Baxter’s Hemopatch Sealing Hemostat Gains Traction in Australia, NZ

Baxter Healthcare has reported a significant surge in the adoption of its room temperature Hemopatch Sealing Hemostat in Australia and New Zealand. Launched in the summer of 2025, this innovative product has quickly become a preferred choice among surgical teams. The convenience and clinical performance of Hemopatch have resonated well with healthcare professionals, marking a notable step forward in surgical practices.

The Hemopatch Sealing Hemostat is an absorbable collagen pad specifically designed for tissue sealing and hemostasis. With its new storage configuration, the product eliminates the need for refrigeration, simplifying both preparation and storage in operating rooms. Surgeons are appreciating its effectiveness in managing mild to moderate bleeding, allowing for increased confidence during procedures.

Surgeons Praise Versatility and Efficiency

A/Prof Matthew Roberts, a urological surgeon based in Queensland, Australia, expressed his satisfaction with the product, stating, “Hemopatch Sealing Hemostat is an excellent product that is quite versatile across many urological operations. The ability to handle venous bleeding across wide surfaces is great for patients and has allowed me to confidently use Hemopatch Sealing Hemostat.” Such endorsements highlight the product’s growing reputation in the surgical community.

Baxter Healthcare emphasizes its commitment to empowering surgical teams by delivering innovative solutions. With a shelf life of up to 36 months, Hemopatch is compatible with both open and minimally invasive procedures, reinforcing its role as a trusted tool in operating rooms throughout the region.

The strong reception of the Hemopatch Sealing Hemostat underscores Baxter’s dedication to providing solutions that enhance patient outcomes. As more surgical teams recognize its value, the product is set to become an integral part of surgical practices in Australia and New Zealand.

For further information on Hemopatch Sealing Hemostat, healthcare professionals can visit the official Baxter website. Baxter Healthcare is committed to continuous innovation, and the successful launch of this product is a testament to their efforts in improving surgical practices.

Baxter and Hemopatch are trademarks of Baxter International Inc. or its subsidiaries. The information provided is intended solely for healthcare professionals and should not be interpreted as medical advice. For specific details on the availability of Hemopatch in other countries, it is advisable to contact local Baxter Healthcare representatives.